Comparative validation of c-kit exon 11 mutation analysis on cytology samples and corresponding surgical resections of gastrointestinal stromal tumours

Cytopathology

Volumn 20, Issue 5, 2009, Pages 297-303

  Pang, N K B ^a   Chin, S Y ^b   Nga, M E ^a   Chang, A R ^a   Ismail, T M ^a,b   Omar, S S ^a,b   Charlton, A ^a   Salto Tellez, M ^a,b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

C kit exon 11 mutation; Diagnostic Molecular Oncology Centre; Fine needle aspiration cytology; Gastrointestinal stromal tumours; Molecular diagnostic cytopathology

Indexed keywords

PARAFFIN; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER SURGERY; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC VALUE; ENDOSCOPIC ECHOGRAPHY; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BIOPSY, FINE-NEEDLE; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 70349094499     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2008.00633.x     Document Type: Article

References (17)

1. Rubin BP, Singer S, Tsao C et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001 61 : 8118 8121.
2. Lasota J, Wozniak A, Sarlomo-Rikala M et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000 157 : 1091 1095.
3. © Pfizer Inc. All rights reserved. http://www.sutent.com/content/ Sutent-P1-Resources-HCP.jsp#onc, 2006.
4. Heinrich MC, Corless CL, Blanke CD et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006 24 : 4764 4774.
5. Salto-Tellez M, Koay ES. Molecular diagnostic cytopathology: definitions, scope and clinical utility. Cytopathology 2004 15 : 252 255.
6. Rader AE, Avery A, Wait CL et al. Fine-needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, immunocytochemistry, and mutational analysis of c-kit. Cancer Cytopathology 2001 93 : 269 275.
7. Gomes AL, Bardales RH, Milanezi F, Reis RM, Schmitt F. Molecular analysis of c-Kit and PDGFRA in GISTs diagnosed by EUS. Am J Clin Pathol 2007 127 : 89 96.
8. Kinoshita K, Isozaki K, Tsutsui S et al. Endoscopic ultrasonography- guided fine needle aspiration biopsy in follow-up patients with gastrointestinal stromal tumours. Eur J Gastroenterol Hepatol 2003 15 : 1189 1193.
9. Geisinger KR, Abdul-Karim FW. Fine needle aspiration biopsies of soft tissue tumors. In : Enzinger and Weiss's Soft Tissue Tumours, 5th edn. Weiss S, Goldblum J (eds). Philadelphia : Mosby 2007 : pp. 103 104.
10. Salto-Tellez M, Nga ME, Han HC et al. Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours. Br J Cancer 2007 96 : 776 782.
11. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999 154 : 53 60.
12. Plaat BE, Hollema H, Molenaar WM et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000 18 : 3211 3220.
13. Bagg A, Kallakury BV. Molecular pathology of leukemia and lymphoma. Am J Clin Pathol 1999 112 : S76 92.
14. Chiu LL, Koay ESC, Chan NL, Salto-Tellez M. Molecular cytopathology: sequencing of the EWS-WT1 gene fusion transcript in the peritoneal effusion of a patient with desmoplastic small round cell tumour. Diagn Cytopathol 2003 29 : 341 343.
15. Chin TM, Anuar D, Soo R et al. Detection of epidermal growth factor receptor variations by partially denaturing HPLC. Clin Chem 2007 53 : 62 70.
16. Lièvre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006 66 : 3992 3995.
17. Dey P. Time for evidence-based cytology. Cytojournal 2007 4 : 1.